Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HRNMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要